Overview: Syndyma 400 mg/16 mL Bevacizumab Injection contains Bevacizumab (400 mg) and is a prescription monoclonal antibody targeted anticancer medicine used in the treatment of various advanced solid tumors including colorectal cancer, non-small cell lung cancer, renal cell carcinoma and ovarian cancer by inhibiting tumor angiogenesis. Key Benefits: – Targets vascular endothelial growth factor (VEGF) to inhibit new blood vessel formation in tumors – Used in combination with chemotherapy for improved outcomes in multiple cancers – Administered under clinical supervision Composition: Bevacizumab (400 mg) How It Works: Bevacizumab is a humanized monoclonal antibody that binds to VEGF, blocking its interaction with receptors on endothelial cells to prevent tumor angiogenesis and reduce tumor growth. Usage Instructions: – Administer only under the supervision of qualified healthcare professionals via intravenous infusion – Follow the prescribed dosing schedule exactly – Not for self-administration Side Effects: – Infusion-related reactions including fever, chills and rash – Hypertension, proteinuria – Increased risk of bleeding and gastrointestinal perforation in rare cases Precautions: – Monitor blood pressure and urine protein regularly during treatment – Not recommended during pregnancy or breastfeeding unless clearly advised by a physician – Inform your doctor of all current medications prior to infusion Storage Instructions: – Store refrigerated between 2-8°C, protect from light, do not freeze Manufacturer: Cipla Ltd Disclaimer: To be sold by retail on the prescription of a registered medical practitioner only.